Badgley Phelps Wealth Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

Badgley Phelps Wealth Managers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$840K	Sell	1,881 -6	-0.3%	-$2.8K	0.02%	211
2025 Q4	$855K	Hold	1,887	–	–	0.02%	206
2025 Q3	$739K	Hold	1,887	–	–	0.02%	201
2025 Q2	$840K	Buy	1,887 +22	+1%	+$10.1K	0.02%	187
2025 Q1	$904K	Sell	1,865 -2	-0.1%	-$932	0.02%	179
2024 Q4	$752K	Sell	1,867 -1	-0.1%	-$464	0.02%	191
2024 Q3	$869K	Sell	1,868 -84	-4%	-$40.4K	0.02%	179
2024 Q2	$915K	Buy	1,952 +100	+5%	+$43.4K	0.02%	169
2024 Q1	$774K	Sell	1,852 -2	-0.1%	-$845	0.02%	176
2023 Q4	$754K	Buy	+1,854	New	+$685K	0.02%	172

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Badgley Phelps Wealth Managers's VRTX Position: Q1 2026 in Review

Badgley Phelps Wealth Managers reduced its Vertex Pharmaceuticals (VRTX) stake by 0.32% in Q1 2026, selling an estimated $2.8K and leaving 1,881 shares worth $840K. The position accounts for 0.02% of the portfolio, ranked #211.

Badgley Phelps Wealth Managers first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $915K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Badgley Phelps Wealth Managers held 1,881 shares of Vertex Pharmaceuticals worth $840K as of Q1 2026.
Badgley Phelps Wealth Managers sold 6 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.8K.
Vertex Pharmaceuticals made up 0.02% of Badgley Phelps Wealth Managers's portfolio in Q1 2026, its #211 holding.
Badgley Phelps Wealth Managers first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Badgley Phelps Wealth Managers's Vertex Pharmaceuticals position peaked at $915K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Badgley Phelps Wealth Managers's 13F filing for Q1 2026, filed 15 Apr 2026.